curcumin in functional dyspepsia

Effect of curcumin on severity of functional dyspepsia; a three blinded clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20080901001165N45

Enrollment

Registered

2020-04-03

Start date

2016-06-09

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional dyspepsia. Functional dyspepsia

Interventions

Intervention 1: Intervention group: curcumin (C3 complex capsules, Sami Labs, India, containing 500 mg curcuminoids and 5 mg bioperine). Intervention 2: Control group: placebo.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of functional dyspepsia according to ROMA III criteria Ruled out organic disorders using upper gastrointestinal endoscopy

Exclusion criteria

Exclusion criteria: Liver dysfunction Renal dysfunction deterioration of dyspepsia and complications during the intervention

Design outcomes

Primary

Measure	Time frame
1.Severity of dyspepsia symptoms. Timepoint: Before intervention, after intervention and 1 month after intervention. Method of measurement: Hong Kong Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactYunes panahi

Bagheiat-allah University of Medical Sciences

Yunespanahi@bmsu.ac.ir+98 21 8805 0435

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026